Rh-Endostatin Combined With Gemcitabine And Platinum In ⅢB And Ⅳ Stage Chemotherapy-Naive Non-Small Cell Lung Cancer

Objective: To investigate the effects and toxicity of recombinanted rh-endostatin combined with Gemcitabine and Platinum regimen for NSCLC.Methods: The 64 cases of Phase IIIB-IV Initial treatment NSCLC from Jan.2005 to Jan. 2010 that met the Inclusion criteria were confirmed by pathology (22 cases were experimental group and 42 cases were control group ), the control groups were treated by GEM plus platinum, the experimental groups were treated by GEM plus platinum combined with rh-endostatin,and the experimental groups were divided into continuous treatment every day and continuous treatment every other day. The result were analyzed by SPSS 13.0 to evaluate hematologic toxicity, liver and kidney function, nausea and loss of appetite, vomiting, short-term efficacy and Lifetime of every group.Result: Result: Of 64 assessable patients, there is no patients can reach in complete response (CR),overall response rate (RR)was 36.3% in trial group and 25.0% in control group(P=0.726), the disease control rate (DCR)were 81.8% in trial group and 83.3% in control group (P=0.374), The median survival time was 19.1months and 15.7months for trial group and control group respectively(P=0.093). In the rh-endostatin was used treatment every day group, overall response rate was 25.0% in trial group and 18.7% in control group(P=0.386), the disease control rate were75.0%in trial group and87.5% in control group(P=0.673), The median survival time was 17.1months and 154.8months for trial group and control group respectively(P=0.192). In the rh-endostatin was used every other day group, overall response rate was 25.0% in trial group and 18.7% in control group(P=0.106), the disease control rate were75.0%in trial group and87.5% in control group(P=0.498),because there was no deaths patients,so in this group,we can't calculate out disease control rate. the result showed that there were no significant statistical difference in hematologic toxicity, liver and kidney function impairment, gastroenteric reaction and treatment effectiveness evaluation of experimental groups and control groups.Conclusion: Rh-endostatin combined with Gemcitabine and Platinum regimen for NSCLC will results in significantly and clinically meaningful improvement in response rate , median time to tumor progression , and will not to increase the chemotherapy Toxicity in patient. but no significance existed ( P > 0.05). Endostar combined Gemcitabine and Cisplatin is the treatment of IIIB and IV at the beginning of an effective program of governance NSCLC, worthy of clinical samples to expand the number of cases for further observation and validation...